liverboystreet Posted - 1 week ago

$XOMA fu xoma

IN0V8 Posted - 2 weeks ago

$XOMA Opportunity Leerink Partners raises target price to $55 from $49

DividendKing77 Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $TKNO $XOMA $SAGE $BMEA

liverboystreet Posted - 10/30/24

$XOMA fu xoma

PenkeTrading Posted - 10/29/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of XOMA Corp. Is that bullish or bearish? $XOMA #XOMA #RsiOverbought #NASDAQ

Doozio Posted - 10/29/24

$XOMA da FUTure of 🧠⏰ is NOW during 🧠⏰♾️. BAHHHing a faatch 💣. Obviously!

TheTradeXchange Posted - 1 month ago

$XOMA XOMAO XOMAP - XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

JordiAGUK Posted - 2 months ago

$ZVRA Interestingly, $XOMA follows the same pattern. On the day they announced they are entitled to receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones.

TheBioFreak Posted - 2 months ago

$XOMA

jhon34263 Posted - 2 months ago

$XOMA

DonCorleone77 Posted - 2 months ago

$ZVRA $XOMA Xoma notes FDA approval of Zevra's MIPLYFFA in patients with NPC XOMA Royalty Corporation (XOMA) announced Zevra Therapeutics (ZVRA) has received approval from the U.S. Food and Drug Administration for MIPLYFFA. MIPLYFFA is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older. It is the sixth commercial asset in XOMA Royalty's growing royalty and milestone portfolio. In June 2023, XOMA Royalty announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol's commercial sales and up to $52.6 million, net, in potential milestone payments from Zevra.

mbadoc Posted - 2 months ago

$XOMA

TheBioFreak Posted - 2 months ago

$XOMA

TheBioFreak Posted - 2 months ago

$XOMA

mbadoc Posted - 3 months ago

$XOMA

epsguid Posted - 3 months ago

$XOMA reported a loss of $0.28, consensus was ($0.26) via @eWhispers #epsmiss http://eps.sh/d/xoma

liverboystreet Posted - 3 months ago

$XOMA fu xoma

NVDAMillionaire Posted - 3 months ago

$XOMA XOMA (NASDAQ:XOMA) Poised for Continued Growth as Royalty Aggregator Model Gains Traction http://beyondspx.com/2024/08/02/xoma-nasdaqxoma-poised-for-continued-growth-as-royalty-aggregator-model-gains-traction/

WaynD01 Posted - 4 months ago

$ZVRA @Mattedbumhair Here is your answer from William Blair on Arimo CRL and how Zevra addressed it. Some for $ARDX board also asked the same question. FYI, $XOMA

WaynD01 Posted - 4 months ago

$XOMA Some analysts' highlights

WaynD01 Posted - 4 months ago

$XOMA If you have ever wondered about your partner $ZVRA : Upcoming FDA Advisory Committee meeting on Aug 02 and PDUFA Sept 21, 2024. Arimoclomol NDA is for a rare disease drug with no approved drug in US and is strongly supported by patients and NPC community with Testimonials and FDA Advocacy ( https://nnpdf.org/wp-content/uploads/2024/02/NNPDF-Community-Response-FDA-Arimoclomol-Review-FINAL.pdf ). Also, the recent guidelines and legalization on rare diseases provide a very good odds for the approval. Now a great entry point brought by the macro socio/economic weaknesses.

WaynD01 Posted - 4 months ago

$ZVRA $XOMA Will these analysts continue reiterate the PT in the evening of Aug 02 after positive Adcom vote and later on Approval? Or will they do something else. You figure it out and decide what to do..

WaynD01 Posted - 4 months ago

$ZVRA $XOMA "He who has ears to hear, let him hear"

erevnon Posted - 4 months ago

HC Wainwright & Co. reiterates XOMA $XOMA at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

liverboystreet Posted - 06/26/24

$XOMA fu xoma

Stocksrunner Posted - 5 months ago

$XOMA Despite an 11.5% loss over the past month, the recent surge indicates strong buying interest. Can this momentum continue? https://stocksrunner.com/symbol/XOMA

Thestocktraderhubzee Posted - 5 months ago

$XOMA Laser Photonics Announces The Launch Of Its Sabertech Laser Cutting Systems, Joining Its Product Lines For Laser Cleaning, Welding, Marking And Engraving Systems

DonCorleone77 Posted - 5 months ago

$XOMA $VIRX $DAWN Xoma receives $8.1M milestone related to Day One's sale of PRV XOMA Corporation (XOMA) announced it has received an $8.1M milestone payment from Viracta Therapeutics (VIRX), related to Day One Biopharmaceuticals' (DAWN) recent sale of its Priority Review Voucher, PRV, for $108 million to an undisclosed buyer. "OJEMDA offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma the only approved therapy studied in and approved specifically for pLGG driven by BRAF fusions," stated Owen Hughes, Chief Executive Officer of XOMA. "With this milestone in hand, we have more than recouped our initial capital outlay. And importantly, we anticipate future royalties on OJEMDA will contribute to a growing portfolio of royalty receipts that will help us drive sustainable free cash flow generation over time."

Drtymax Posted - 5 months ago

$LADXD $CYTR far better deal with $XOMA on Aldox

DonCorleone77 Posted - 5 months ago

$XOMA LadRx, ImmunityBio mutually agree to terminate Aldoxorubicin license The company states: "LadRx is pleased to announce that the Company and NantCell, Inc., together with NantCell's parent company ImmunityBio, Inc., have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin. In 2023, LadRx transferred the royalty and milestone rights of arimoclomol and aldoxorubicin to XOMA Corporation (XOMA) in exchange for $5 million in upfront gross proceeds, up to an additional $2 million for milestones related to arimoclomol and $5 million for milestones related to aldoxorubicin. XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx. In parallel, LadRx and XOMA have amended their 2023 Royalty Purchase Agreement to provide XOMA with a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage of any economics derived by LadRx from future out-license agreements related to aldoxorubicin. The agreement between LadRx and XOMA regarding future royalties and milestones associated with arimoclomol is not affected by the termination of the aldoxorubicin license between LadRx and NantCell."